Trexquant Investment LP Buys 20,875 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Trexquant Investment LP raised its stake in AtriCure, Inc. (NASDAQ:ATRC) by 27.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 98,206 shares of the medical device company’s stock after purchasing an additional 20,875 shares during the period. Trexquant Investment LP owned 0.20% of AtriCure worth $3,001,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Heck Capital Advisors LLC acquired a new position in AtriCure in the 4th quarter valued at about $60,000. Venturi Wealth Management LLC boosted its holdings in shares of AtriCure by 1,337.6% during the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company’s stock worth $69,000 after acquiring an additional 2,100 shares during the period. KBC Group NV grew its position in shares of AtriCure by 65.3% in the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company’s stock valued at $72,000 after purchasing an additional 932 shares during the last quarter. R Squared Ltd bought a new position in shares of AtriCure during the fourth quarter worth approximately $89,000. Finally, AlphaQuest LLC lifted its holdings in AtriCure by 855.1% during the 4th quarter. AlphaQuest LLC now owns 5,062 shares of the medical device company’s stock worth $155,000 after purchasing an additional 4,532 shares during the last quarter. 99.11% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ATRC shares. Needham & Company LLC reiterated a “buy” rating and set a $51.00 price objective on shares of AtriCure in a research report on Thursday, March 27th. JPMorgan Chase & Co. dropped their price objective on shares of AtriCure from $51.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, March 27th. Canaccord Genuity Group cut their price objective on shares of AtriCure from $66.00 to $52.00 and set a “buy” rating for the company in a report on Friday, March 28th. Piper Sandler raised their target price on shares of AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $60.00 price target on shares of AtriCure in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $49.44.

AtriCure Stock Performance

Shares of NASDAQ:ATRC opened at $31.31 on Monday. AtriCure, Inc. has a 1 year low of $18.94 and a 1 year high of $43.11. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -32.96 and a beta of 1.65. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. The company’s 50 day simple moving average is $37.28 and its 200 day simple moving average is $34.21.

Insider Activity

In related news, Director Karen Prange sold 6,100 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the sale, the director now directly owns 17,828 shares of the company’s stock, valued at $679,603.36. This trade represents a 25.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 3.20% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.